Ophthalmic Business News

Ray Therapeutics has closed an oversubscribed $100 million Series A financing round to advance the company’s optogenetic gene therapy programs targeting blinding retinal diseases, according to a press release.

The FDA approved Miebo for the treatment of signs and symptoms of dry eye disease, Bausch + Lomb and Novaliq announced in a press release.

Alimera Sciences acquired the U.S. commercialization rights for Yutiq, a treatment for chronic noninfectious uveitis affecting the posterior segment, from EyePoint Pharmaceuticals, according to a press release.

SAN DIEGO — In this Healio Video Perspective from Eyecelerator@ASCRS, Anthony Wallace of Bausch + Lomb provides an update on the company’s activities.

Susan MacDonald, MD, Cathleen McCane, MD, Laura M. Periman, MD, and Dagny Zhu, MD, chat about meeting hacks live from ASCRS.

Investors often hear the phrase “don’t put all your eggs in one basket,” and interpret it as a warning against owning too much of one individual stock in a portfolio.

SAN DIEGO — In this Healio Video Perspective from Eyecelerator@ASCRS, Norbert Lowe and Michael Rowe of Eyenovia announce the FDA approval of Mydcombi, an ophthalmic spray designed to induce mydriasis.

The FDA has accepted a supplemental biologics license application from Genentech for Vabysmo for the treatment of macular edema following retinal vein occlusion, according to a company press release.

The FDA accepted a new drug application for iDose TR, an intraocular implant designed to continuously deliver travoprost to lower IOP in open-angle glaucoma or ocular hypertension, according to a Glaukos press release.

Norlase received FDA 510(k) clearance and CE mark approval for its Echo green pattern laser photocoagulator, according to a press release.